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Melhem Solh,1 Sanjay Oommen,1 Rachel Isaksson Vogel,2 Ryan Shanley,2
Navneet S. Majhail,1 Linda J. Burns1The prognosis of recipients of allogeneic hematopoietic cell transplantation (HCT) who require mechanical
ventilation (MV) has historically been poor. Of 883 adults undergoing allogeneic HCT at the University of
Minnesota between 1998 and 2009, 179 (20%) required MV before day 100 posttransplantation. We evalu-
ated the outcomes of these patients to develop a prognostic index to predict the 100-day post-MV overall
survival (OS) based on factors present at the time of MV. The 179 patients were divided at random into
a training set (n 5 119) and a validation set (n 5 60). The 100-day postventilation OS was 17% for the total
population. Multivariate Cox regression on the training set identified creatinine\2 mg/dL and platelet count
.20 109/L as significant predictors of better OS. Recursive partitioning classified patients with these good
prognostic criteria into class A (n5 76); all other patients were classified as class B (n5 103). Among class A
patients, 100-day OS was 29% in the training set and 30% in the validation set. Corresponding OS in class B
patients was 5% and 15%, respectively. This prognostic index should help guide physicians in counseling HCT
patients and their families regarding the use of MV and potential outcomes.
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Hematopoietic cell transplantation (HCT) is the
treatment of choice for a variety of high-risk hemato-
logic diseases and malignancies. HCT is associated
with possible infectious and noninfectious complica-
tions that often lead to respiratory failure. An
estimated 6%-30% of HCT recipients develop respi-
ratory failure and require endotracheal intubation
and mechanical ventilation (MV) [1-9]. The overall
prognosis of HCT recipients requiring MV has been
dismal, with reported survival rates of only 3%-26%
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6/j.bbmt.2012.02.009Minnesota that included patients who underwent
HCT before 1993, only 3% of patients who received
MV (n 5 191) survived 6 months after extubation,
and all patients age $40 years or intubated within
90 days of HCT died by day 100 postextubation [4].
Previous studies have reported on the outcomes of
HCTrecipients requiring intensive care unit admission
and have identified factors that predict a risk of greater
mortality [2,3,8]. These factors include the need for
MV, need for hemodynamic support, and organ
failure. Recent studies have reported improved
outcomes of HCT recipients who receive MV,
with survival rates as high as 26% [3,11-13]. This
improvement may be attributed to advances in critical
care and MV support. In the non-HCT setting, pa-
tients cared for by intensivists in an intensive care unit
have been shown to have better outcomes compared
with patients cared for by those not trained in critical
care [14]. Other advances in critical care, such as the
use of lower tidal volume in acute respiratory distress
syndrome, have been shown to improve outcomes in
patients receiving MV [15]. These new reports are en-
couraging, and despite the fact that survival rates re-
main disappointingly low for HCT recipients on MV,
it can be argued that ventilation in a select group of
HCT recipients should not be considered futile.
The use of MV in HCT recipients has been called
into question on the basis of ethical and economic con-
cerns [4]. In the present study, we analyzed outcomes
Biol Blood Marrow Transplant 18:1378-1384, 2012 1379Mechanical Ventilation and Hematopoietic Cell Transplantationfor adult HCT recipients who requiredMVwithin the
first 100 days posttransplantation. We sought to iden-
tify prognostic factors that will help guide physicians
and assist patients and their families in discussing
long-term prognosis.PATIENTS AND METHODS
Patient Population
Consecutive adult patients (age .18 years) under-
going first allogeneic HCT at theUniversity ofMinne-
sotabetween January1998 and June2009were included
in this analysis. The study was approved by the univer-
sity’s Institutional Review Board. Patients who had
undergone a previous autologous HCTwere excluded.
Of 883 adult recipients, 179 (20.3%) required MV
within 100 days of transplantation and were included
in this analysis. Patients who required MV after 100
days posttransplantation were excluded, because our
patients return to their home institution at that time
point, and thus subsequent data are incomplete.
Patient demographic and clinical outcomes data
were collected prospectively from the University of
Minnesota’s blood and marrow transplant database. A
detailed chart review of additional data for all patients
who received MV was conducted by 3 of the authors
(M.S., S.O, and L.B.). Disease risk was categorized as
standard risk or high risk. Standard-risk disease in-
cluded acute leukemia in first complete remission and
chronic myelogenous leukemia in first chronic phase;
high-risk disease included all other diagnoses.
To be eligible for myeloablative conditioning at
our center, patients must have a Karnofsky score of
$90%, a diffusing capacity of the lung for carbonmon-
oxide (DLCO) of.50% of predicted, a left ventricular
ejection fraction of $45%, liver function tests #2
times the upper limit of normal, and a creatinine level
#2 mg/dL or creatinine clearance .40 mL/min by
urine collection. For reduced-intensity conditioning,
patients must have a Karnofsky score of $60%,
a DLCO of.30% of predicted, a left ventricular ejec-
tion fraction of$35%, liver function tests#2 times the
upper limit of normal, and a creatinine level#2mg/dL
or creatinine clearance.40 mL/min. Patients must be
negative for human immunodeficiency virus infection.
Patients had an HLA-matched related or unrelated
donor or an umbilical cord blood (UCB) graft.
Supportive care included anti-infective prophylaxis
in single hospital rooms with high-efficiency particu-
late air filtration. Antiviral prophylaxis included acy-
clovir until day 100 posttransplantation. Documented
cytomegalovirus (CMV) reactivation or infection was
treated with ganciclovir or foscarnet. Broad-spectrum
antibiotics were administered for neutropenic fever,
and antifungal coverage was added for persistent fever.
All patients received fluconazole or voriconazole forfungal infections prophylaxis and trimethoprim-
sulfamethoxazole for Pneumocystis jiroveci prophylaxis.
Extended-spectrum fluoroquinolones were adminis-
tered for encapsulated bacterial prophylaxis during
treatment of graft-versus-host disease (GVHD). After
HCT, patients routinely received granulocyte colony-
stimulating factor and transfusion of irradiated blood
products for hemoglobin\8 g/dL and platelet count
of\10  109/L. All patients who were intubated or
required organ failure support remained physically in
the Bone Marrow Transplant inpatient unit under the
primary care of the HCT team, with pulmonary and
critical care specialists, as well as other subspecialty ser-
vices, providing consultative support on a daily basis.
Reason for MV, Organ Dysfunction, and Support
The reason for MV was categorized as pulmonary
(acute respiratory failure from any cause), central ner-
vous system (CNS) compromise, procedure (need for
airway support during a surgical procedure), infection
(nonpulmonary), or other. Of the 4 patients undergo-
ing surgical procedures, 1 patient had a tongue biopsy,
2 had a laparotomy, and 1 had a pericardial window.
Data for organ dysfunction collected during the first
72 hours of MV included any lung or blood infection,
hepatic dysfunction, renal dysfunction, neutrophil
engraftment, platelet recovery, and poor nutritional
status. Infections were defined as growth in culture.
Hepatic dysfunction was defined as total bilirubin .4
mg/dL (68 mmol/L), and renal dysfunction was defined
as creatinine .2 mg/dL during the initial 72 hours of
MV [7]. Neutrophil engraftment was defined as an ab-
soluteneutrophil count of.500109/L for 3days, and
platelet engraftment was defined as a platelet count of
$20  109/L without transfusion. An albumin level
\3g/dLwas an indicator of poor nutritional status.Or-
gan failure support data collected, in addition to MV,
included the need for vasopressor support (defined as
the infusion of dopamine .3 mg/kg/min or norepi-
nephrine, epinephrine, phenylephrine, dobutamine,
amrinone, vasopressin, or milrinone [10]), and dialysis.
Patients who were extubated for comfort measures or
withdrawal of care were considered never extubated.
Statistical Methods
To develop a prognostic index, patients were ran-
domly divided into 2 groups. Two-thirds were assigned
to the training set (n 5 119) to develop the index, and
the remaining third were assigned to the validation set
(n 5 60) to assess the index. The outcome of interest
for the prognostic index was overall survival (OS) at
100 days post-MV. Event times were calculated from
the date of MV to the date of death or censored at 100
days for those who lived beyond 100 days. Univariate
Cox regression models were used to reduce the initial
number of potential predictors to be considered in the
multivariate analysis to those with a P value\.20 or
Table 1. Patient Characteristics before HCT
Characteristic n (%)
Number of patients 179
Sex
Male 102 (57)
Female 77 (43)
Age, years
<40 75 (42)
$40 104 (58)
Karnofsky score
<90% 42 (23)
$90% 137 (77)
Body mass index
<30 123 (69)
$30 54 (31)
Missing 2
Year of HCT
1998-2003 97 (54)
2004-2009 82 (46)
Disease
Acute leukemia 99 (55)
Chronic leukemia 28 (16)
Lymphoma 36 (20)
Myeloma 5 (3)
Other* 11 (6)
Disease
Standard risk 40 (22)
High risk 139 (78)
Type of allogeneic transplant
Related 77 (43)
Unrelated 27 (15)
UCB 75 (42)
Conditioning
Myeloablative 124 (69)
Reduced-intensity 55 (31)
TBI use
Yes 163 (91)
No 16 (9)
Conditioning + TBI use
Myeloablative + 1320 cGy TBI 110 (61)
Myeloablative without TBI 14 (8)
Reduced-intensity, none or 200 cGy TBI 55 (31)
Donor/recipient CMV
2/2 60 (34)
2/+ 72 (40)
+/2 13 (7)
+/+ 34 (19)
DLCO, % of predicted
<70 54 (31)
$70 123 (69)
Missing 2
FEV1/FVC ratio
<60 2 (1)
60-80 99 (56)
>80 76 (43)
Missing 2
*Otherdiseases included aplastic anemia (n54), inheritedmetabolic dis-
orders (n 5 2), myelofibrosis (n 5 2), and renal cell carcinoma (n5 3).
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considered included sex, age (\40 or $40 years), Kar-
nofsky score (\90% or $90%), year of HCT (1998-
2003 or 2004-2009), disease risk (standard or high),
type of transplant (related, unrelated, or UCB), condi-
tioning at transplantation (myeloablative conditioning
with 1320 cGy of total body irradiation [TBI], myeloa-
blative conditioning without TBI, or reduced-intensity
conditioning with 200 cGy TBI), donor (D) and recip-
ient (R) CMV status (D-/R-, D-/R1, D1/R-, D1/R1),
DLCO (\70% or $70% of predicted), forced expira-
tory volume in 1 second/forced vital capacity ratio
(FEV1/FVC) (\60%, 60%-80%, or .80% of pre-
dicted), reason for MV, time from transplantation to
MV (\30 days or 30-100 days), grade II or higher acute
GVHD before MV, neutrophil engraftment before
MV, and laboratory tests at the time of MV, including
total bilirubin (\4 mg/dL or $4 mg/dL), albumin
(\3 g/dL or $ 3g/dL), platelet count (\20  109/L
or $20  109/L, indicative of platelet engraftment),
and creatinine (\2 mg/dL or$2 mg/dL). Multivariate
Cox regression and recursive partitioning were used on
the training set to build a model that classified patients
into good (class A) and poor (class B) prognosis groups
[16,17]. Once agreement on the optimal predictors was
established using the 2 methods, the final model was
assessed in the validation set.
Kaplan-Meier estimates for 100-day post-MV OS
are reported for each class and compared by the log-
rank test [18]. Patient and transplant characteristics
were compared by class using c2 and Fisher exact tests
for categorical data as appropriate. All analyses were
performed using SAS version 9.2 (SAS Institute,
Cary, NC) and R version 2.7 (R Institute for Statistical
Computing, Vienna, Austria).
RESULTS
Patient Characteristics at Baseline and Time
of MV
The baseline characteristics before HCT for the
179 patients who required MV are presented in
Table 1. The majority of patients had good perfor-
mance status and high-risk disease. The most common
sources of progenitor cells were matched related do-
nors and UCB. The majority of patients underwent
myeloablative conditioning.
The patient characteristics at time of MV are pre-
sented in Table 2. The most common reason for MV
was pulmonary (ie, acute respiratory failure from any
cause). The majority of patients required ventilation
before 30 days post-HCT and had engrafted both neu-
trophils and platelets at the time of MV.
Predictors of OS
The 100 day post-MV OS was 17% (95%
Confidence Interval [CI] 12-23%) for all patients(n 5 179). Univariate Cox regression analyses identi-
fied standard disease risk, UCB transplant, FEV1/
FVC ratio .60, total bilirubin\4 mg/dL at time of
MV, creatinine \2 mg/dL at time of MV, platelet
count .20  109/L at time of MV, albumin $3 g/dL
at time of MV, and no acute GVHD grade II or higher
beforeMVas predictors of improvedOS in the training
set (P\ .20 for all) (Table 3). The reason for MV was
not predictive for OS (P 5 .39), even when the cause
was analyzed as pulmonary versus nonpulmonary
Table 2. Patient Characteristics at the Time of MV
Characteristic n (%)
Number of patients 179
Reason for mechanical ventilation
Pulmonary 138 (77)
CNS 19 (11)
Procedure 4 (2)
Infection 7 (4)
Other 11 (6)
Time from HCT
<30 days 105 (59)
30-100 days 74 (41)
Total bilirubin, mg/dL
<4 86 (48)
$4 93 (52)
Creatinine, mg/dL
<2 106 (59)
$2 73 (41)
Neutrophil engraftment
Yes 107 (60)
No 72 (40)
Platelet count,  109/L
<20 48 (27)
$20 131 (73)
Albumin, g/dL
<3 105 (59)
$3 74 (41)
Acute GVHD grade II-IV before MV
No 45 (25)
Yes 134 (75)
Neutrophil engraftment refers to absolute neutrophil count >500/mL for
3 days.
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set found creatinine (\2 mg/dL or $2 mg/dL) and
platelet count (\20  109/L or $20  109/L) to be
significant predictors of OS.
Results of Recursive Partitioning and Survival
Outcomes by Prognostic Class
In agreement with the final multivariate Cox re-
gression model, recursive partitioning of the training
set showed that patients with a creatinine\2 mg/dL
and platelet count$20 109/L at time ofMV had sig-
nificantly better OS (Figure 1). Patients meeting these
criteria were placed in class A; the remaining patients
were placed in class B. OS at 100 days post-MV was
significantly higher for class A (29% in the training
set and 30% in the validation set) compared with class
B (5% in the training set and 15% in the validation set)
(Table 4). There was distinct separation of the 2 clas-
ses’ respective survival curves up to day 100 post-MV
in both the training and validation sets (P \ .0001
and P 5 .0242, respectively) (Figure 2).
Course of MV by Prognostic Class
The patients in class B, the poor risk group (n 5
103), were more likely to develop hepatic and renal
dysfunction compared with those in class A (n 5 76),
and less likely to be extubated (Table 5). There was
a trend toward a greater need for vasopressors in the
class B. No between-group difference in infections,
need for dialysis, development of chronic GVHD, or
time on MV was detected.DISCUSSION
Our data indicate that the presence of renal dys-
function and lackof platelet recovery at timeofMVpre-
dicted a worse outcome in HCT recipients. We have
identified a simple tool to separate patients requiring
MVearly posttransplantation into good and poor prog-
nostic groups. Furthermore, many patient, disease, and
transplantation variables were not predictive, including
reason for MV, age, disease risk, type of conditioning,
previous history of acute GVHD, and progenitor cell
source. This information is also important when care
teams are counseling patients and their families.
The initiation, duration, and withdrawal ofMV are
areas of both medical and ethical concern, given the
high accompanying mortality rate [6]. Indeed, the his-
torically poor outcomes have led some to suggest that
the decision to withdraw care can be made unilaterally
in patients with poor prognostic features [4,19,20].
Our results, derived from a large cohort of patients
undergoing HCT during a period when advanced
critical care support systems were used uniformly,
can assist transplant physicians in determining the
prognosis of a patient when the need for MV arises.
They also can provide a basis for discussing prognosis
with the patient and family members when making
decisions about MV as a critical care intervention.
The OS of HCT recipients who received MV was
significantly worse than the reported OS of 69% in
5183 unselected patients who receivedMV formultiple
reasons [21].Multiorgandysfunctionwas reported tobe
a poor prognostic indicator in intubated patients who
didnot undergoHCT[22].Twowidely usedorgan fail-
ure severity scoresused to estimatemortality in ICUpa-
tients, the Simplified Acute Physiology Score II (SAPS
II) and Logistic Organ Dysfunction (LOD) score, were
found to underestimate mortality in HCT recipients
[13], and the Acute Physiology and Chronic Health
Evaluation (APACHE) III score is reported to have
only moderate prognostic capability [11]. This is likely
related to the unique characteristics of transplant recip-
ients, who have already been hospitalized for some time
on the transplant service, have received cytotoxic and/or
immunosuppressive agents with known renal and he-
patic toxicities, and have hematopoietic compromise.
Predictors of survival in HCT recipients who re-
ceive MV have been the cornerstone of many previous
studies aiming to identify a subset of patientswith a very
high mortality rate. Pene et al. [13] reported that time
fromHCT to ICU admission of.30 days, use of vaso-
active drugs, and elevated serum bilirubin were all pre-
dictors of higher in-hospital mortality. Other reported
prognostic features associated with mortality in HCT
recipients who receive MV include age $21 years [6]
and$40 years [4], bacterial versus other causes of infec-
tion [23], durationofMV.4days [24], time fromHCT
toMV [4], hepatic and renal injury, use of vasopressors
Table 3. Predictors of OS in the Training Set
Number
of Patients
Odds Ratio
(95% Confidence
Interval) P Value
Total 119
Sex .99
Male 66 1.00
Female 53 1.00 (0.67-1.49)
Age, years .39
18-39 53 0.84 (0.57-1.25)
$40 66 1.00
Karnofsky score .37
<90% 28 1.23 (0.78-1.95)
$90% 91 1.00
Body mass index .45
<30 81 1.00
$30 36 1.18 (0.77-1.83)
Year of HCT .39
1998-2003 66 1.00
2004-2009 53 1.19 (0.80-1.76)
Disease .18
Standard risk 24 0.70 (0.42-1.17)
High risk 95 1.00
Type of allogeneic transplant .07
Related 48 1.21 (0.79-1.87)
Unrelated 19 1.92 (1.10-3.35)
UCB 52 1.00
Conditioning + TBI use .91
Myeloablative + 1320
cGy TBI
73 0.92 (0.59-1.42)
Myeloablative without TBI 10 1.02 (0.48-2.15)
Reduced-intensity, none or
200 cGy TBI
36 1.00
Donor/recipient CMV .96
–/– 40 1.03 (0.58-1.82)
–/+ 53 0.92 (0.53-1.59)
+– 5 0.89 (0.30-2.63)
+/+ 21 1.00
DLCO .87
<70% 41 0.97 (0.64-1.45)
$70% 77 1.00
Missing 1
FEV1/FVC ratio .16
<60 2 2.15 (0.51-9.01)
60-80 62 0.75 (0.50-1.11)
>80 54 1.00
Missing 1
Reason for MV .39
Pulmonary 89 1.00
CNS 13 1.41 (0.77-2.60)
Procedure 3 0.66 (0.16-2.69)
Infection 6 1.74 (0.46-4.02)
Other 8 0.71 (0.31-1.64)
Time from HCT to MV .50
<30 days 71 0.87 (0.59-1.30)
30-100 days 48 1.00
Total bilirubin at MV, mg/dL .03
<4 56 0.64 (0.43-0.95)
$4 63 1.00
Creatinine at MV, mg/dL <.0001
<2 77 0.43 (0.29-0.65)
$2 41 1.00
Neutrophil engraftment at MV .60
No 47 1.11 (0.75-1.65)
Yes 72 1.00
Platelet count at MV,  109/L .06
<20 32 1.52 (0.98-2.34)
$20 87 1.00
Albumin at MV, g/dL .09
<3 67 1.41 (0.95-2.11)
$3 52 1.00
(Continued )
Table 3. (Continued )
Number
of Patients
Odds Ratio
(95% Confidence
Interval) P Value
Acute GVHD grade II-IV
before MV
.01
Yes 34 1.72 (1.13-2.64)
No 85 1.00
Neutrophil engraftment refers to absolute neutrophil count >500/mL for
3 days.
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the stemcell source [25]. Agewas not predictive ofmor-
tality in the present study or in several other studies
[24,26-28], but this might have been obscured by the
use of reduced-intensity conditioning in almost one-
third of our patients. In the present study, time from
HCT to MV was not predictive of worse outcome.
Moreover, 60% of our patients were intubated within
30 days of transplantation, compared with only 38%
in the study of Pene et al. [13]. Vasoactive drug support
was required by 25% of our patients but by 74% of the
patients in the study of Pene et al. [13]; in both studies,
vasoactive drug support was a poor prognostic indica-
tor. Many of these differences are likely related to
different patient populations (eg, haploidentical recip-
ients and patients requiring noninvasive ventilation in
the Pene et al. study), as well as to the type and duration
of supportive care. Furthermore, themore recent use of
bilevel positive airway pressure might be affecting the
frequency and use of intubation such that the most
problematic patients are ultimately intubated.OS = overall survival at 100 days postmechanical  ventilation 
Class A: Creatinine < 2 mg/dL AND platelets 
 20 x109/L at time of mechanical ventilation
Class B: Creatinine  2 mg/dL OR platelets < 20 x109/L at time of mechanical ventilation 
Training Set 
N = 119 
OS at 100 days: 16% 
Creatinine <2 mg/dL
N = 77 
OS at 100 days: 23% 
Creatinine 2 mg/dL
N = 42 
OS at 100 days: 2% 
Class B 
Platelets 20 x 109/L
N = 56 
OS at 100 days: 29% 
Class A 
Platelets <20 x 109/L
N = 21 
OS at 100 days: 10% 
Class B
Figure 1. Results of recursive partitioning on the training set. The OS
of 119 patients in the training set is shown, based on the prognostic in-
dicators obtained through recursive portioning. Patients are divided into
class A (good prognosis; creatinine\2 mg/dL and platelets$20 109/L
at time of MV) and class B (poor prognosis; creatinine $2 mg/dL or
platelets\20  109/L at time of MV).
Table 4. Kaplan-Meier Estimates of OS at 100 Days Post-MV by Prognostic Class
Class
Training Set Validation Set
Patients, n (%) OS (95% CI), % HR (95% CI) Patients, n (%) OS (95% CI), % HR (95% CI)
A 56 (47) 29 (17-41) 1.00 20 (33) 30 (12-50) 1.00
B 63 (53) 5 (1-12) 2.54 (1.68-3.84) 40 (66) 15 (6-28) 2.02 (1.07-3.79)
CI indicates confidence interval; HR, hazard ratio.
Biol Blood Marrow Transplant 18:1378-1384, 2012 1383Mechanical Ventilation and Hematopoietic Cell TransplantationA more recent concern has been the outcome of
UCB HCT with the ever-increasing use of this pro-
genitor cell source. In the present study, 42% of our
population requiring MV underwent UCB transplan-
tation, compared with \10% in all other studies.
Thus, our report is the first to include such a high
percentage of UCB recipients, and our results are
encouraging. Stem cell source was not a predictor of
outcome, with similar outcomes reported in recipients
of matched related donor, matched unrelated donor,
and UCB transplants.
The heterogeneity of the published retrospective
series on the outcomes and predictors of survival in
HCT recipients who receive MV remains one of the
limiting factors in identifying a validated set of prog-
nostic indicators.We split our population into a valida-
tion set and a training set to identify a set of variablesFigure 2. Kaplan-Meier OS through 100 days post-MV by prognostic
class. (A) Training set (n 5 119). This graph shows a significantly better
OS in class A patients compared with class B patients. (B) Validation set
(n5 60), also showing a significantly better OS in class A patients com-
pared with class B patients.that are reproducible in HCT recipient populations.
This can help eliminate the lack of validation, which
is a common limitation in analyzing retrospective
cohorts, in which chance associations rather than
true associations are uncovered [29]. In an attempt to
validate reported predictors of mortality in HCT
recipients who received MV, in 2001 Bach et al. [10]
abstracted poor prognostic features from 15 English-
language articles published between 1988 and 2000,
and then estimated the probability of mortality in the
presence of poor prognostic features in a validation
cohort of 226 patients from 5 medical centers across
the United States. The presence of simultaneous he-
patic and renal dysfunction was associated with the
highest probability of death. In the Bach et al. valida-
tion cohort, 29%of the patients underwent autologous
HCT and 12% had a solid tumor. For uniformity in
patient populations, we confined our population to al-
logeneic transplant recipients undergoing HCT for
hematologicmalignancies, and also restricted the years
of transplantation to 1998-2009, when supportive care
methods were more uniformly applied.
This study has some limitations that must be ad-
dressed. First, although we validated our prognosticTable 5. Patient Characteristics during the Course of MV by
Prognostic Class
Class A, n (%) Class B, n (%) P Value
Number of patients 76 103
Any blood or lung infection .52
No 31 (61) 47 (46)
Yes 45 (39) 56 (54)
Vasopressor support .06
No 62 (82) 71 (69)
Yes 14 18 32 (31)
Liver failure <.01
No 45 (59) 38 (37)
Yes 31 (41) 65 (63)
Renal failure .05
No 37 (49) 35 (34)
Yes 39 (51) 68 (66)
Hemodialysis .34
No 51 (67) 62 (60)
Yes 25 (33) 41 (40)
Chronic GVHD .78
No 71 (93) 94 (91)
Yes 5 (7) 9 (9)
Extubated <.01
No 44 (58) 90 (87)
Yes, later reintubated 5 (7) 1 (1)
Yes 27 (35) 12 (12)
Time on MV .39
#7 days 33 (42) 50 (49)
>7 days 44 (58) 53 (51)
1384 Biol Blood Marrow Transplant 18:1378-1384, 2012M. Solh et al.factors, the validation set was a cohort of patients who
underwent HCT in the same institution and following
the same protocols. Validation must now be addressed
in a multicenter patient population to determine gen-
eralizability. Second, our outcomes were interpreted
and compared with those in previous cohorts from
our hospital [4] and other institutions. These historical
cohorts differ from our data subset, given that we tend
to perform a higher percentage of UCB transplants.
Although donor stem cell source was not found to
a predictor of mortality in patients receiving MV, his-
torically transplantation-related mortality has been
higher in UCB transplant recipients than in other
stem cell transplant recipients [30]. Third, our patient
population might have been too small to allow us to
identify other predictive factors that did not reach sta-
tistical significance.
In conclusion, with the advent of improved means
of supportive and intensive care, in conjunctionwith di-
verse conditioning regimens and progenitor cell sour-
ces for HCT recipients, it is imperative that we
develop prognostic tools for outcomes to guide physi-
cians. Our findings can serve as general guidelines for
discussing the need for and benefits ofMVwith patients
and their families, as well as with HCT and intensive
care teams.Further validationofour data in larger num-
bers of patients at multiple transplant centers is needed.
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